常染色体显性多囊肾病:放射科医生应了解的内容
本文综述常染色体显性多囊肾病(ADPKD)的发病机制、诊断挑战与治疗进展,指出超声、CT 和 MRI 在监测疾病进展中的关键作用,并提出通过 MRI 引导的肾脏容积分析来监测托伐普坦延缓肾功能恶化疗效的设想。
要点
- 超声、CT 和 MRI 在监测 ADPKD 疾病进展中起关键作用。
- 高达一半的肾实质可丧失而肾功能无明显异常。
- 作者提出用 MRI 引导的肾脏容积分析监测托伐普坦疗效。
核心结论
- 影像学(超声、CT、MRI)在 ADPKD 诊断和监测疾病进展中具有关键作用,作者提出通过 MRI 引导的肾脏容积分析来监测托伐普坦延缓肾功能恶化的疗效。
研究设计与样本
- 综述类文章,讨论 ADPKD 的发病机制、诊断挑战、新治疗选择及通过连续影像监测疾病进展。
临床应用与阅片要点
- 作者提出通过 MRI 引导的肾脏容积分析监测 ADPKD 患者中托伐普坦延缓肾功能恶化速度的疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Autosomal dominant polycystic kidney disease (ADPKD) is the most common renal genetic disorder and a leading cause of end stage renal failure (ESRF) affecting over 12 million people worldwide. Whilst the mainstay of diagnosis has historically favoured the imaging domain, the progression of disease was until very recently thought to be best monitored via biochemical analysis, i.e. measurement of estimated glomerular filtration rate. Imaging modalities such as sonography, CT and MRI have more recently proven to be key in monitoring disease progression. As much as half of the renal parenchyma can be lost with no real derangement in renal function. Tolvaptan, a vasopressin antagonist has been shown to slow disease progression and preserve renal function. Here we discuss at length the pathogenesis of ADPKD, the various diagnostic challenges surrounding its evaluation, new treatment options and monitoring of disease progression via serial imaging. We also propose monitoring of the efficacy of Tolvaptan at slowing the rate of deterioration in renal function in patients with ADPKD through MRI guided volumetric analysis of the kidneys.
引用
- Gaur P, Gedroyc W, Hill P, et al. ADPKD-what the radiologist should know. Br J Radiol. 2019. PMID: 31039325. doi:10.1259/bjr.20190078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。